Clinical Trial Update: SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating SYD985 in HER2-expressing recurrent, advanced, or metastatic endometrial cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer

Drugs mentioned

• SYD985 (trastuzumab duocarmazine)

Snippet

Sponsor: Byondis B.V. | Conditions: Endometrial Cancer | Phase 2 | Status: COMPLETED | Results posted: 2024-05-30